EPRX

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week ("DDW") Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). Oral Presentation: Lecture Session: EoE: Advances in Managemen

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3) demonstrated a robust response in both tissue health and symptom response compared to their baseline levels.Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the RESOLVE trial.Clinical remission in symptoms was maintained in 66% of the patients (2 of 3) in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks.EP-104GI continues to be well tolerated by patie

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Raymond James Biotech Innovation SymposiumFormat: 1x1 MeetingsDate: April 14, 2026Location: New York, NY 2026 Bloom Burton & Co. Healthcare Investor ConferenceFormat: Presentation & 1x1 MeetingsDate: April 21 - 22, 2026Presentatio

William Blair initiated coverage of Eupraxia Pharmaceuticals with a rating of Outperform

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study.Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline (as measured by SDI, where a 3 point reduction is clinical remission).Across dose cohorts 4-9, the decrease in symptom response is the highest at 24 weeks, compared to earlier timepoints. This underlines the value of continuous and steady steroid exposure to reduce infl

40-F - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise. "2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our ne

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the "Common Shares"), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to pu

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the pricing of its previously announced public offering (the "Offering") of 6,428,574 common shares of the Company (the "Common Shares") at a price to the public of US$7.00 per Common Share and pre-funded warrants to purchase up to 1,428,571 Common Shares in lieu thereof (the "Pre-Funded Warrants") at a price of US$6.99999 per Pre-Funded Warra

SUPPL - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated February 5, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of common shares (the "Common Shares") of the Company (or pre-funded warrants to purchase Common Shares in lieu

SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

S-8 - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1.At lower doses, patients maintained the improvements in tissue health1 reported at week 12 out until week 36. Clinical remission2 was achieved by 8 weeks and maintained through 52 weeks in the majority of patients for which more than 60% of their esophagus was treated.EP-104GI continues to be well tolerated by patients receiving the drug; over 200 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"), and no cases of oral candidiasis. VICTORIA, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pha

SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)